Stem cell transplant with nivolumab for children with relapsed Hodgkin lymphoma
Tests nivolumab, with or without bendamustine, before stem cell transplant in children with Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
Key facts
- Where
- Moscow and Saint Petersburg, RussiaSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 18 years old?
Source: NCT06931613, who can take part
Where in Russia
- N. N. Blokhin Russian Cancer Research Center, Moscow, RussiaMoscow, RussiaNo longer taking part
- Pavlov University, RM Gorbacheva Research InstituteSaint Petersburg, RussiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Petersburg State Pavlov Medical University
- Trial code
- NCT06931613
- Record updated
- 17 April 2025
- Original description
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.Read full original descriptionShow less
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment With or Without Bendamustine
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.
Inclusion: Diagnosis of Hodgkin lymphoma established on the basis of histological and immunohistochemical studies; Confirmation of relapsed of refractory Hodgkin lymphoma based on histological and immunohistochemical studies or based on imaging methods (PET/CT and/or CT); Number of previous lines of therapy >2; Karnofsky index ≥60%; availability of signed informed consent -.
Exclusion: Number of previous lines of therapy ≤ 2; Intolerance to drugs used in the study; Presence of concomitant severe disease; Presence of HIV and/or viral hepatitis (B or C); Karnofsky index < 60; Presence of a second tumor; Pregnancy or lactation; Participation in another study within six months.